Back to Search
Start Over
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS®) plus ribavirin (COPEGUS®) for 16 or 24 weeks
- Source :
- Liver International. 29:237-241
- Publication Year :
- 2009
- Publisher :
- Wiley, 2009.
-
Abstract
- Background: Hepatic steatosis is common in patients infected with hepatitis C virus (HCV). The effect of steatosis on anti-HCV therapy efficacy is unclear. Methods: We studied host and viral factors associated with steatosis and the effect of steatosis on treatment efficacy using the database of a large prospective trial in patients with HCV genotypes 2 and 3. Results: Out of 885 patients assessed for steatosis, a total of 614 patients or 69% had steatosis. Patients with genotype 3 were more likely to have steatosis than those with genotype 2 (79 vs. 59%, P
- Subjects :
- medicine.medical_specialty
Pathology
Genotype
Hepatitis C virus
Hepacivirus
Interferon alpha-2
medicine.disease_cause
Gastroenterology
Polyethylene Glycols
chemistry.chemical_compound
Internal medicine
Ribavirin
medicine
Humans
Univariate analysis
Hepatology
business.industry
Body Weight
Fatty liver
Age Factors
Interferon-alpha
virus diseases
Hepatitis C
Viral Load
medicine.disease
Recombinant Proteins
digestive system diseases
Fatty Liver
Logistic Models
chemistry
Steatosis
business
Viral hepatitis
Viral load
Subjects
Details
- ISSN :
- 14783231 and 14783223
- Volume :
- 29
- Database :
- OpenAIRE
- Journal :
- Liver International
- Accession number :
- edsair.doi.dedup.....85104c35297489846a69e410bff34794